Trial Profile
Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine.
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 13 Sep 2019
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacodynamics
- 20 Nov 2018 Status changed from active, no longer recruiting to completed.
- 14 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 14 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.